BIODESIX for BIODESIX
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 18, 2019 | $59,235 | Replaced |
| 3rd Quarter - Termination | Jun 27, 2020 | $60,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
-Regulation of laboratory developed tests (Verifying Accurate, Leading-edge IVCT Development (VALID) Act discussion draft)
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE JONES | — |
Medicare/Medicaid MMM
-Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93) -payment of laboratory tests in surprise billing legislation (S.1895; H.R. 3630) -Update packaging policy for protein-based tests (CY 2018 OPPS/ASC final rule) -Preserve current laboratory date of service policy (CY 2020 OPPS proposed rule)
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE JONES | — |
Copyright/Patent/Trademark CPT
- Discussion draft to reform Section 101 of the Patent Act concerning patent eligibility
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE JONES | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.